Munger Mode rating: 3 out of 5 — Hold. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Price caveat. Sources conflict on the post-earnings price. One reported ~$234.67 after the Oct 22 release. Another reported ~$242 in premarket trading. I use ~$235 below. At $242 the case is slightly weaker. At $225 it is slightly better. Nothing changes the rating inside that band. Quest is a business we understand. It is also better than most S&P 500 companies. It runs one of two national clinical-laboratory networks in the US. Its volumes are steady, its customers need the service, and management has been competent and unflashy. We like that. Our problem is price and economics. At ~$235 the stock trades at about 21x the midpoint of 2026 adjusted EPS guidance ($11.25–$11.35). The business earns operating margins in the mid-teens and returns on invested capital around 10–11%. That is a respectable business. It is not a compounding machine that deserves a premium multiple.
Recent filings analysed: 10-Q (2026-10-23), 8-K (2026-10-22), 8-K (2026-10-22), 8-K (2026-07-23).
Stock screener · Superinvestor 13F holdings · Analyst sentiment